MK-677 (Ibutamoren)


Orally active non-peptide ghrelin receptor agonist

A Merck-developed orally bioavailable non-peptide ghrelin receptor agonist that produces sustained GH and IGF-1 elevation with once-daily oral dosing.

Abstract

MK-677 (Ibutamoren; CAS 159752-10-0; molecular formula C27H36N4O5S; molecular weight 528.66) is a non-peptide ghrelin receptor agonist developed by Merck in the 1990s. Unlike the peptide GHRPs, MK-677 is orally bioavailable and produces sustained GH and IGF-1 elevation over 24 hours with once-daily dosing. Phase 2 trials in elderly subjects showed sustained increases in GH, IGF-1, and lean body mass over 12 to 24 month treatment periods. The compound did not advance to FDA approval; the program was deprioritized after disappointing Phase 3 results in the GHD elderly population. The compound is sold as a research chemical/dietary supplement in some markets, though FDA has issued warnings against its sale as a supplement. Pharmacokinetics: plasma half-life 4 to 6 hours; high oral bioavailability; hepatic CYP3A4 metabolism. Adverse events include increased appetite, water retention, and modest insulin resistance with chronic high-dose use.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph